Increased Endothelial Nitric-Oxide Synthase Expression Reduces Hypertension and Hyperinsulinemia in Fructose-Treated Rats

Department of Internal Medicine and Institute of Hypertension, Tongji Hospital, Tongji Medical College of Huazhong , University of Science and Technology, Wuhan, People's Republic of China.
Journal of Pharmacology and Experimental Therapeutics (Impact Factor: 3.97). 12/2008; 328(2):610-20. DOI: 10.1124/jpet.108.143396
Source: PubMed


Endothelial dysfunction and decreased production of nitric oxide (NO) by endothelial NO synthase (eNOS) are implicated in the pathogenesis of hypertension and insulin resistance. Because the potential influence of increased eNOS expression/activity on these parameters is unclear, the present study examined the effects of eNOS gene therapy on insulin resistance and blood pressure alterations in a fructose-induced hypertension model in rats. As predicted, 2 weeks of fructose consumption in the drinking water resulted in elevated systolic blood pressure and insulin resistance. These and other physiologic alterations were reversed within 2 weeks after a single intravenous injection of a vector containing the human eNOS cDNA (pcDNA3.1-eNOS), whereas injection of an empty vector (pcDNA3.1) was without effect. In support of the beneficial effects of pcDNA3.1-eNOS treatment being because of enhanced eNOS expression and activity, increased eNOS protein levels were documented in aorta, liver, kidney, and heart of fructose-treated rats injected with pcDNA3.1-eNOS, and corresponding elevations in nitrite/nitrate and cGMP concentrations were observed in urine. Furthermore, pcDNA3.1-eNOS treatment prevented fructose-induced decreases in expression levels of insulin receptor substrate-1, the p110 catalytic subunit of phosphatidylinositol 3-kinase, phosphorylated Akt, and phosphorylated AMP-activated protein kinases in liver, aorta, and skeletal muscle. The results of this study cumulatively indicate that gene therapy with human eNOS decreased fructose-induced hypertension and insulin resistance in rats and suggest potential signaling pathways that mediate these effects. These data highlight the potential utility of eNOS gene therapy in the treatment of hypertension and insulin resistance.

Download full-text


Available from: Matthew L Edin, Mar 19, 2014
21 Reads
  • Source
    • "Blood pressure was measured by Non-invasive Tail cuff method using the IN125/R NIBP System which was used in conjunction with a PowerLab system to obtain non-invasive blood pressure measurement from rats. NIBP utilizes a specialized tail cuff and pulse transducer to intermittently measure blood pressure based on the periodic occlusion of tail blood flow [Zhao et al., 2009]. Normal blood pressures of all the rats were recorded as baseline blood pressure and were recorded again after drugs treatment for four weeks. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The anti-anginal effects of Allopurinol were assessed in experimental model rats of angina and their effects were evaluated with Amlodipine. In the vasopressin-induced angina model, oral administration of Allopurinol in dose of 10 mg /kg revealed remarkably analogous effects in comparison to Amlodipine like dose-dependent suppression of vasopressin-triggered time, duration and severity of ST depression. In addition, Allopurinol produced dose dependent suppression of plasma Malandialdehyde (MDA) level, systolic blood pressure, cardiac contractility and cardiac oxygen consumption; while in contrast, Amlodipine minimally suppressed the elevation of plasma MDA level. Endothelial NO synthase (eNOS) expression, serum nitrate were strikingly increased, however lipid profile were significantly reduced. Seemingly, Allopurinol was found to be more potent than Amlodipine – a calcium channel antagonist. To conclude, it was explicitly observed and verified that on the ischemic electrocardiography (ECG) changes in angina pectoris model in rats, allopurinol exerts a significant protective effects, reminiscent of enhancement of vascular oxidative stress, function of endothelial cells, improved coronary blood flow in addition to the potential enhancement in myocardial stress. Moreover, our findings were in conformity with several human studies.
    Saudi Pharmaceutical Journal 01/2015; 2. DOI:10.1016/j.jsps.2014.12.001 · 1.28 Impact Factor
  • Source
    • "EGB ameliorated vascular inflammation by downregulation of ET-1 as well as ICAM-1, VCAM-1, and E-selectin expressions in thoracic arota. Several studies have shown that lowering blood pressure and endothelial functions are related to an increase of eNOS reactivity, thereby increasing NO production roles as a strong vasodilator [25, 26]. In the present study, EGB upregulated eNOS levels in the aorta and recovered the HF diet-induced impairment of endothelium-dependent vasorelaxation. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Overconsumption of fructose results in dyslipidemia, hypertension, and impaired glucose tolerance, which have documented correlation with metabolic syndrome. Gastrodia elata, a widely used traditional herbal medicine, was reported with anti-inflammatory and antidiabetes activities. Thus, this study examined whether ethanol extract of Gastrodia elata Blume (EGB) attenuate lipid metabolism and endothelial dysfunction in a high-fructose (HF) diet animal model. Rats were fed the 65% HF diet with/without EGB 100 mg/kg/day for 8 weeks. Treatment with EGB significantly suppressed the increments of epididymal fat weight, blood pressure, plasma triglyceride, total cholesterol levels, and oral glucose tolerance, respectively. In addition, EGB markedly prevented increase of adipocyte size and hepatic accumulation of triglycerides. EGB ameliorated endothelial dysfunction by downregulation of endothelin-1 (ET-1) and adhesion molecules in the aorta. Moreover, EGB significantly recovered the impairment of vasorelaxation to acetylcholine and levels of endothelial nitric oxide synthase (eNOS) expression and induced markedly upregulation of phosphorylation AMP-activated protein kinase (AMPK) α in the liver, muscle, and fat. These results indicate that EGB ameliorates dyslipidemia, hypertension, and insulin resistance as well as impaired vascular endothelial function in HF diet rats. Taken together, EGB may be a beneficial therapeutic approach for metabolic syndrome.
    Evidence-based Complementary and Alternative Medicine 02/2014; 2014:101624. DOI:10.1155/2014/101624 · 1.88 Impact Factor
    • "Improved endothelial function and reduced inflammatory load by SYM treatment seemed to protect the HFr animals from IRS associated thrombotic complications. It is well known that HFr feeding attenuates PI3K-Akt signaling pathway and cause insulin resistance, cell adhesion, migration, proliferation , survival and classical preconditioning response following MI-RP injury (Gao et al., 2002; Hausenloy and Yellon, 2004; Zhao et al., 2009). Previous reports from this group confirmed that long term fructose diet feeding reduced Akt and eNOS expression in the heart Fig. 5. Effect of silymarin on infarct size and cardiac injury biomarkers in fructose fed rats. "
    [Show abstract] [Hide abstract]
    ABSTRACT: High dietary fructose causes insulin resistance syndrome (IRS), primarily due to simultaneous induction of genes involved in glucose, lipid and mitochondrial oxidative metabolism. The present study evaluates effect of a hepatoprotective agent, silymarin (SYM) on fructose-induced metabolic abnormalities in the rat and also assessed the associated thrombotic complications. Wistar rats were kept on high fructose (HFr) diet throughout the 12-week study duration (9 weeks of HFr feeding and subsequently 3 weeks of HFr plus SYM oral administration [once daily]). SYM treatment significantly reduced the HFr diet-induced increase expression of peroxisome proliferator-activated receptor gamma coactivator (PGC)-1α/β, peroxisome proliferator-activated receptor (PPAR)-α, forkhead box protein O1 (FOXO1), sterol regulatory element binding protein (SREBP)-1c, liver X receptor (LXR)-β, fatty acid synthase (FAS) and PPARγ genes in rat liver. SYM also reduced HFr diet mediated increase in plasma triglycerides (TG), non-esterified fatty acids (NEFA), uric acid, malondialdehyde (MDA), total nitrite and pro-inflammatory cytokines (C-reactive protein [CRP], interleukin-6 [IL-6], interferon-gamma [IFN-γ] and tumor necrosis factor [TNF]) levels. Moreover, SYM ameliorated HFr diet induced reduction in glucose utilization and endothelial dysfunction. Additionally, SYM significantly reduced platelet activation (adhesion and aggregation), prolonged ferric chloride-induced blood vessel occlusion time and protected against exacerbated myocardial ischemia reperfusion (MI-RP) injury. SYM treatment prevented HFr induced mRNA expression of hepatic PGC-1α/β and also its target transcription factors which was accompanied with recovery in insulin sensitivity and reduced propensity towards thrombotic complications and aggravated MI-RP injury.
    European journal of pharmacology 01/2014; 727(1). DOI:10.1016/j.ejphar.2014.01.038 · 2.53 Impact Factor
Show more